Cefixime
- Product NDC
- 70518-4759
- Requested package NDC
- 70518-4759-0
- 11-digit product format
- 705184759
- Labeler code
- 70518
- Product ID
- 70518-4759_5c114a0a-eb6c-507a-e063-6294a90a8231
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Cefixime
- Dosage form
- CAPSULE
- Route
- ORAL
- Labeler
- REMEDYREPACK INC.
- Application
- ANDA217607
- Marketing category
- ANDA
- Marketing start
- 2026-09-21
- Substance
- CEFIXIME
- Active strength
- 400 mg/1
- Pharmacologic classes
- Cephalosporin Antibacterial [EPC], Cephalosporins [CS]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A217607-001 | CEFIXIME | CEFIXIME | 400MG | CAPSULE / ORAL | AB | 2026-03-23 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A217607-001 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A217607-001 | CEFIXIME | 400MG | CAPSULE / ORAL | AB | 2026-03-23 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A217607-001 | CEFIXIME | 400MG | CAPSULE / ORAL | AB | 2026-03-23 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A217607-001 | CEFIXIME | 400MG | CAPSULE / ORAL | AB | 2026-03-23 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A217607-001 | CEFIXIME | 400MG | CAPSULE / ORAL | AB | 2026-03-23 | caaa826d4ba7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A217607-001 | CEFIXIME | 400MG | CAPSULE / ORAL | AB | 2026-03-23 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A217607-001 | AB | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A217607-001 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A217607-001 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A217607-001 | AB | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A217607-001 | AB | 1 | a50c72e98297… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Cefixime
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| CEFIXIME | 400 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 97I1C92E55 | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 409823 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| a5128554-118a-4d8e-8425-c0000037c59d | Available on FDA.report |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Cefixime | CEFIXIME | REMEDYREPACK INC. | a5128554-118a-4d8e-8425-c0000037c59d | 2026-09-22 | Warnings, Adverse reactions | 217607 ANDA217607 70518-4759-0 70518-4759 70518475900 |
| Cefixime | CEFIXIME | Aurobindo Pharma Limited | 9cdb156f-7a99-413e-b49a-ffafaf9e93fe | 2026-03-25 | Warnings, Adverse reactions | 217607 ANDA217607 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 70518-4759-0 | 70518475900 | 2 CAPSULE in 1 BOTTLE, PLASTIC (70518-4759-0) | 2 capsule | 2026-09-21 | No | No | Current |